77877-20-4

Basic information

• Product Name: 2-Oxazolidinone,4-methyl-3-(1-oxopropyl)-5-phenyl-, (4R,5S)-
• Synonyms: 2-Oxazolidinone,4-methyl-3-(1-oxopropyl)-5-phenyl-, (4R-cis)-;(4R,5S)-4-Methyl-5-phenyl-3-propionyl-2-oxazolidinone
• CAS NO: 77877-20-4
• Molecular Formula: C₁₃H₁₅NO₃
• Molecular Weight: 233.2631
• Product Categories: Peptide
• Mol File: 77877-20-4.mol
• Article Data: 45

Chemical Properties

• Boiling Point: 394.4°C at 760 mmHg
• Flash Point: 192.3°C
• Appearance: /
• Density: 1.161 g/mL at 20 °C(lit.)
• Vapor Pressure: 1.98E-06mmHg at 25°C
• Refractive Index: 1.535
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-Oxazolidinone,4-methyl-3-(1-oxopropyl)-5-phenyl-, (4R,5S)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Oxazolidinone,4-methyl-3-(1-oxopropyl)-5-phenyl-, (4R,5S)-(77877-20-4)
• EPA Substance Registry System: 2-Oxazolidinone,4-methyl-3-(1-oxopropyl)-5-phenyl-, (4R,5S)-(77877-20-4)

Safety Data

• Safety Statements: 23-24/25
• WGK Germany: 3
• F: 10
• Hazardous Substances Data: 77877-20-4(Hazardous Substances Data)

Usage

Description

2-Oxazolidinone,4-methyl-3-(1-oxopropyl)-5-phenyl-, (4R,5S)is a complex organic compound characterized by its unique molecular structure, which features an oxazolidinone ring, a methyl group, a phenyl group, and a propionyl group. 2-Oxazolidinone,4-methyl-3-(1-oxopropyl)-5-phenyl-, (4R,5S)is known for its potential applications in various fields due to its chemical properties and reactivity.

Uses

Used in Pharmaceutical Industry:
2-Oxazolidinone,4-methyl-3-(1-oxopropyl)-5-phenyl-, (4R,5S)is used as a reactant in the synthesis of Lactimidomycin, a potent translation and cell migration inhibitor. This application is significant because Lactimidomycin has shown promise in the development of new therapeutic strategies for various diseases, including cancer and other conditions characterized by abnormal cell migration and proliferation.
In the synthesis of Lactimidomycin, the compound (4R,5S)-4-Methyl-5-phenyl-3-propionyl-2-oxazolidinone serves as a key building block, contributing to the overall structure and biological activity of the final product. Its unique properties and reactivity make it an essential component in the development of this potent inhibitor, highlighting its importance in the pharmaceutical industry.

InChI:InChI=1/C13H15NO3/c1-3-11(15)14-9(2)12(17-13(14)16)10-7-5-4-6-8-10/h4-9,12H,3H2,1-2H3/t9-,12-/m1/s1

Upstream product

• 598-26-5 dimethylketene 
• 24423-87-8 3,4-dihydro-isoquinoline 2-oxide 
• 77943-39-6 4-methyl-5-phenyloxazolidin-2-one 
• 79-03-8 propionyl chloride 
• 123-62-6 propionic acid anhydride 
• 40626-29-7 Acutrim 
• 37577-28-9 (1S,2R)-(+)-norphedrine 
• 116782-32-2 (1S,2R)-1-phenyl-2-<(ethoxycarbonyl)amino>propanol 
• 492-39-7 (1S,2S)-2-amino-1-phenylpropanol 
• 54418-69-8 4-methyl-5-phenyl-2-oxazolidinone 
• 16251-45-9 (4S,5R)-4-methyl-5-phenyl-oxazolidin-2-one 
• 802294-64-0 propionic acid 
• 492-41-1 (1R,2S)-norephedrine 
• 4122-52-5 1-(1H-imidazol-1-yl)propan-1-one 

Downstream Products

• 138694-16-3 (4R,5S)-3-<(2R,3R,4E)-3-Hydroxy-2-methyl-5-phenyl-4-pentenoyl>-4-methyl-5-phenyl-2-oxazolidinone 
• 80719-70-6 (4R,5S)-3-<(2S)-1-oxo-2,4-dimethylpent-4-enyl>-4-methyl-5-phenyloxazolidin-2-one 
• 80719-70-6 (4R,5S)-3-((R)-2,4-Dimethyl-pent-4-enoyl)-4-methyl-5-phenyl-oxazolidin-2-one 
• 77877-24-8 (4R,5S)-[(2R,3S)-3-hydroxy-2-methylheptanoyl]-4-methyl-5-phenyl-2-oxazolidinone 
• 80697-95-6 (4R,5S)-4-methyl-3-((S)-2-methylpent-4-enoyl)-5-phenyloxazolidin-2-one 
• 129985-93-9 <3(2R,3S,4E),4R,5S>-3-(3-hydroxy-2-methyl-1-oxo-4-heptenyl)-4-methyl-5-phenyl-2-oxazolidinone 
• 121444-36-8 (4R,5S)-4-methyl-3-<(2R)-2-methyl-4-heptynoyl>-5-phenyl-2-oxazolidinone 
• 121444-33-5 (4R,5S)-4-methyl-3-<(2S)-2-methyl-4-heptynoyl>-5-phenyl-2-oxazolidinone 
• 101212-35-5 (2S,4R,5S)-3-(3-phenylthiomethyl-1-oxopropyl)-5-phenyl-oxazolidin-2-one 
• 101212-35-5 (4R,5S)-4-Methyl-3-((R)-2-methyl-3-phenylsulfanyl-propionyl)-5-phenyl-oxazolidin-2-one 
• 115820-52-5 (4R,5S)-3-<(2R,3R)-3-(2,5-Dimethoxy-3-nitrophenyl)-3-hydroxy-2-methylpropanoyl>-4-methyl-5-phenyl-2-oxazolidinone 
• 115889-49-1 (4R,5S)-3-[(2R,3S)-3-(2,5-Dimethoxy-3-nitro-phenyl)-3-hydroxy-2-methyl-propionyl]-4-methyl-5-phenyl-oxazolidin-2-one 
• 115889-48-0 (4R,5S)-3-[(2S,3S)-3-(2,5-Dimethoxy-3-nitro-phenyl)-3-hydroxy-2-methyl-propionyl]-4-methyl-5-phenyl-oxazolidin-2-one 
• 115889-47-9 (4R,5S)-3-[(2S,3R)-3-(2,5-Dimethoxy-3-nitro-phenyl)-3-hydroxy-2-methyl-propionyl]-4-methyl-5-phenyl-oxazolidin-2-one 

Relevant articles and documents

Thermal proteome profiling efficiently identifies ribosome destabilizing oxazolidinones

Identifying the targets of bioactive small molecules is a challenging endeavor for which no general solution currently exists. Classical affinity purification experiments suffer from the need to functionalise a bioactive compound and link it to a solid support, which may interfere with target binding. A modern mass spectrometry-based proteomics technique that has partially circumvented this problem is thermal proteome profiling (TPP), which determines the effect of an unmodified small molecule on the thermal stability of the whole proteome simultaneously. Here, we use TPP to identify the mode-of-action of a newly-discovered autophagy inhibitor based on oxazolidinones often employed as chiral auxiliaries. Surprisingly, a significant portion of all ribosomal proteins were found to be destabilized by the inhibitor, highlighting the utility of this technology for determining a challenging mode-of-action.

NOVEL CONNECTED BODY AND USE THEREOF IN SPECIFIC CONJUGATION BETWEEN BIOMOLECULE AND DRUG

PROBLEM TO BE SOLVED: To provide: a method for producing a connected body; a method for using the connected body in the production of a uniform conjugate; and a method for applying the conjugate in the treatment of cancer, infectious diseases, and autoimmune diseases. SOLUTION: A novel connected body is provided that includes a 2,3-di-substituted succinic acid group or a 2-mono-substituted or 2,3-di-substituted fumaric acid or maleic acid (trans (E)- or cis (Z)-butenedioic acid) group for conjugating 2 or more compounds/cytotoxic agents per connected body with a cell-binding molecule by specifically bridge-linking to a pair of thiol on the cell-binding molecule. The connected body is exemplified by the following general formula. SELECTED DRAWING: None COPYRIGHT: (C)2021,JPOandINPIT

CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE

What provided is the conjugation of cytotoxic to a cell-binding molecule with a bis-linker(dual-linker) as shown in Formula (I). It provides bis-linkage methods of making a conjugate of a cytotoxic drug molecule to a cell-binding agent in a specific manner. It also relates to application of the conjugates for the treatment of a cancer, or an autoimmune disease, or an infectious disease.